Literature DB >> 8160609

Association between lipoprotein(a) and progression of coronary artery disease in middle-aged men.

C Marburger1, R Hambrecht, J Niebauer, M Schoeppenthau, E Scheffler, K Hauer, G Schuler, G Schlierf.   

Abstract

The association between lipoprotein(a) (Lp[a]) and progression of coronary artery disease (CAD) compared with other serum lipids was evaluated in 104 patients with angiographically proven coronary atherosclerosis. Patients were randomized to either an intervention or a control group. The 12-month intervention program consisted of a low-fat diet and daily physical exercise. Patients in the control group received "usual care" by their private physician. Eighty-three patients (36 in the intervention and 47 in the control group) underwent repeat angiography after 1 year. Angiographically documented net regression was seen in 13 patients (8 in the intervention and 5 in the control group), no change was seen in 40 patients (21 in the intervention and 19 in the control group) and progression was noted in 30 patients (7 in the intervention and 23 in the control group). No correlation could be shown between Lp(a) and angiographically documented progression of the disease. In a multivariate analysis including metabolic variables, group assignment, age and smoking habits, only assignment to the intervention group (p = 0.0075) and a decrease in total cholesterol (p = 0.0167) were independently associated with the course of the disease. Patients with or without previous myocardial infarction (70 vs 34) did not differ in Lp(a) levels (median 9.15 vs 14.25 mg/dl). Patients with Lp(a) > 25 mg/dl were younger than patients with Lp(a) < or = 25 mg/dl (52 vs 55 years; p < 0.03), indicating a connection between Lp(a) and the development of premature CAD.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8160609     DOI: 10.1016/0002-9149(94)90874-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Angiographic trials of lipid-lowering therapy: end of an era?

Authors:  G R Thompson
Journal:  Br Heart J       Date:  1995-10

2.  Lipoprotein(a) is related to the extent of lesions in the coronary vasculature and to unstable coronary syndromes.

Authors:  J D Zampoulakis; A A Kyriakousi; K A Poralis; N T Karaminas; I D Palermos; E T Chimonas; D V Cokkinos
Journal:  Clin Cardiol       Date:  2000-12       Impact factor: 2.882

3.  Lipoprotein (A): Better assessor of coronary heart disease risk in south Indian population.

Authors:  D Rajasekhar; K S S Saibaba; P V L N Srinivasa Rao; S A A Latheef; G Subramanyam
Journal:  Indian J Clin Biochem       Date:  2004-07

4.  Lipoprotein(a) for risk assessment in patients with established coronary artery disease.

Authors:  Michelle L O'Donoghue; David A Morrow; Sotirios Tsimikas; Sarah Sloan; Angela F Ren; Elaine B Hoffman; Nihar R Desai; Scott D Solomon; Michael Domanski; Kiyohito Arai; Stephanie E Chiuve; Christopher P Cannon; Frank M Sacks; Marc S Sabatine
Journal:  J Am Coll Cardiol       Date:  2013-10-23       Impact factor: 24.094

5.  Serum lipoprotein(a) concentrations are related to coronary disease progression without new myocardial infarction.

Authors:  A Tamura; T Watanabe; Y Mikuriya; M Nasu
Journal:  Br Heart J       Date:  1995-10

6.  Reference Materials for the Standardization of the Apolipoproteins A-I and B, and Lipoprotein(a).

Authors:  Francesco Dati; Jillian Tate
Journal:  EJIFCC       Date:  2001-12-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.